Observational studyJournal of cancer research and clinical oncology2026
Ondansetron oral soluble pellicles vs. azasetron for preventing nausea and vomiting in patients receiving antitumor therapies: a comparative observational study.
Observational study in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectiveOndansetron oral soluble pellicles (OSP) show satisfactory effects on preventing nausea and vomiting following antitumor therapies. This study aimed to compare the antiemetic efficacy and safety profiles of ondansetron OSP vs. azasetron in patients receiving antitumor therapies.
methodsA total of 110 patients who received antitumor therapies were included in this comparative observational study. According to patient willingness, disease status, and tolerance, 55 patients received ondansetron OSP, and the other 55 patients received intravenous azasetron. During acute and delayed phases, the function living index emesis (FLIE) scale score and degrees of nausea and vomiting [high (46-63 points), moderate (19-45 points), or low (0-18 points)] were assessed. Adverse reactions were collected.
resultsDuring the acute phase, FLIE-nausea (5.7 ± 8.9 vs. 17.9 ± 13.6) and vomiting (6.9 ± 7.8 vs. 17.6 ± 13.9) domain scores were lower in patients receiving ondansetron OSP than those receiving azasetron (both P < 0.001). The degrees of nausea and vomiting were lower in patients receiving ondansetron OSP than those receiving azasetron (both P < 0.05). During the delayed phase, FLIE-nausea (5.0 ± 7.9 vs. 10.8 ± 9.1) and vomiting (4.2 ± 6.6 vs. 9.2 ± 8.7) domain scores were lower in patients receiving ondansetron OSP than those receiving azasetron (both P < 0.001). Regarding adverse reactions, the incidence of constipation was lower in patients receiving ondansetron OSP than those receiving azasetron (7.3% vs. 30.9%) (P = 0.003), but the incidence of headache did not differ (P = 0.113).
conclusionOndansetron OSP possess superior antiemetic effects and safety profiles to azasetron in patients receiving antitumor therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.